title: The DEXLIFE study methods: identifying novel candidate biomarkers that predict progression to type 2 diabetes in high risk individuals.
abstract: The incidence of type 2 diabetes (T2D) is rapidly increasing worldwide and T2D is likely to affect 592 million people in 2035 if the current rate of progression is continued. Today, patients are diagnosed with T2D based on elevated blood glucose, either directly or indirectly (HbA1c). However, the information on disease progression is limited. Therefore, there is a need to identify novel early markers of glucose intolerance that reflect the underlying biology and the overall physiological, metabolic and clinical characteristics of progression towards diabetes. In the DEXLIFE study, several clinical cohorts provide the basis for a series of clinical, physiological and mechanistic investigations in combination with a range of--omic technologies to construct a detailed metabolic profile of high-risk individuals across multiple cohorts. In addition, an exercise and dietary intervention study is conducted, that will assess the impact on both plasma biomarkers and specific functional tissue-based markers. The DEXLIFE study will provide novel diagnostic and predictive biomarkers which may not only effectively detect the progression towards diabetes in high risk individuals but also predict responsiveness to lifestyle interventions known to be effective in the prevention of diabetes.
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark.
authors.forename: G S
authors.initials: GS
authors.lastname: Andersen
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark.
authors.forename: T
authors.initials: T
authors.lastname: Thybo
authors.affiliation: Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
authors.forename: H
authors.initials: H
authors.lastname: Cederberg
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark.
authors.forename: M
authors.initials: M
authors.lastname: Orešič
authors.affiliation: Cancer Epigenetics and Biology Program, Spanish Biomedical Research Centre Network for Epidemiology and Public Health, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Esteller
authors.affiliation: Institute for Research in Biomedicine, Barcelona, Spain; Departament de Bioquímica I Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Zorzano
authors.affiliation: Voluntary Health Insurance Board, Dublin, Ireland.
authors.forename: B
authors.initials: B
authors.lastname: Carr
authors.affiliation: University of Newcastle-on-Tyne, Newcastle, UK.
authors.forename: M
authors.initials: M
authors.lastname: Walker
authors.affiliation: Metabolon Inc., Durham, NC, USA.
authors.forename: J
authors.initials: J
authors.lastname: Cobb
authors.affiliation: Pintail Ltd., Blackrock, Co., Dublin, Ireland.
authors.forename: C
authors.initials: C
authors.lastname: Clissmann
authors.affiliation: Centre for Preventive Medicine, School of Health and Human Performance, Dublin City University, Dublin, Ireland.
authors.forename: D J
authors.initials: DJ
authors.lastname: O'Gorman
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark. Electronic address: JJNL@steno.dk.
authors.forename: J J
authors.initials: JJ
authors.lastname: Nolan
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000032:analysis*; D016022:Case-Control Studies; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control; D004035:Diet Therapy; D018450:Disease Progression; D005081:Exercise Therapy; D005260:Female; D018149:Glucose Intolerance / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D011236:Prediabetic State / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors; D040242:Risk Reduction Behavior; D055815:Young Adult
chemical_list: D015415:Biomarkers
keywords: Biomarkers; Lifestyle intervention; Prevention; Type 2 diabetes